A Study of RPL554 in Patients With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

November 3, 2017

Study Completion Date

November 3, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

RPL554

RPL554 suspension administered using a nebuliser

DRUG

Placebo

Placebo solution administered using a nebuliser

Trial Locations (1)

Papworth Hospital, Cambridge

All Listed Sponsors

collaborator

Cystic Fibrosis Trust

OTHER

lead

Verona Pharma plc

INDUSTRY

NCT02919995 - A Study of RPL554 in Patients With Cystic Fibrosis | Biotech Hunter | Biotech Hunter